Variability in the CIITA gene interacts with HLA in multiple sclerosis

Genes and Immunity

Volumn 15, Issue 3, 2014, Pages 162-167

  Gyllenberg, A ^a,c   Piehl, F ^a   Alfredsson, L ^a   Hillert, J ^a   Bomfim, I L ^a   Padyukov, L ^a   Orho Melander, M ^b   Lindholm, E ^b   Landin Olsson, M ^b   Lernmark, A ^b   Olsson, T ^a   Kockum, I ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CIITA; HLA; interaction; multiple sclerosis

Indexed keywords

HLA A ANTIGEN; HLA DRB1 ANTIGEN; HLA ANTIGEN; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CIITA GENE; CLEC16A GENE; CONTROLLED STUDY; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; CASE CONTROL STUDY; EPISTASIS; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENETICS; GENOTYPE; IMMUNOLOGY; RISK;

ALLELES; CASE-CONTROL STUDIES; EPISTASIS, GENETIC; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HLA ANTIGENS; HUMANS; LINKAGE DISEQUILIBRIUM; MULTIPLE SCLEROSIS; NUCLEAR PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANS-ACTIVATORS;

EID: 84899586524     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2013.71     Document Type: Article

References (52)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005; 37: 1108-1112.
3. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008; 131(Pt 12): 3118-3131.
4. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
5. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000; 55: 140-148.
6. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012; 8: 602-612.
7. DeSandro A, Nagarajan UM, Boss JM. The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. Am J Hum Genet 1999; 65: 279-286.
8. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 2004; 34: 1513-1525.
9. Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato K et al. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 1997; 6: 591-600.
10. LeibundGut-Landmann S, Waldburger JM, Reis e Sousa C, Acha-Orbea H, Reith W. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nat Immunol 2004; 5: 899-908.
11. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37: 486-494.
12. Eike MC, Skinningsrud B, Ronninger M, Stormyr A, Kvien TK, Joner G et al. CIITA gene variants are associated with rheumatoid arthritis in Scandinavian populations. Genes Immun 2012; 13: 431-436.
13. Gyllenberg A, Asad S, Piehl F, Swanberg M, Padyukov L, Van Yserloo B et al. Age-dependent variation of genotypes in MHC II transactivator gene (CIITA) in controls and association to type 1 diabetes. Genes Immun 2012; 13: 632-640.
14. Skinningsrud B, Husebye ES, Pearce SH, McDonald DO, Brandal K, Wolff AB et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J Clin Endocrinol Metab 2008; 93: 3310-3317.
15. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-1201.
16. Harrison P, Pointon JJ, Farrar C, Harin A, Wordsworth BP. MHC2TA promoter polymorphism (-168*G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 409-411.
17. Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL et al. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet 2006; 33: 59-61.
18. Bronson PG, Ramsay PP, Seldin MF, Gregersen PK, Criswell LA, Barcellos LF. CIITA is not associated with risk of developing rheumatoid arthritis. Genes Immun 2011; 12: 235-238.
19. Bronson PG, Caillier S, Ramsay PP, McCauley JL, Zuvich RL, De Jager PL et al. CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. Hum Mol Genet 2010; 19: 2331-2340.
20. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
21. International Multiple Sclerosis Genetics Consortium (IMSGC). Refining genetic associations in multiple sclerosis. Lancet Neurol 2008; 7: 567-569.
22. Patsopoulos NA, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J et al. Genomewide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011; 70: 897-912.
23. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353-1360.
24. Gobin SJ, Peijnenburg A, Keijsers V, van den Elsen PJ. Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 1997; 6: 601-611.
25. Zuvich RL, Bush WS, McCauley JL, Beecham AH, De Jager PL, Ivinson AJ et al. Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex. Hum Mol Genet 2011; 20: 3517-3524.
26. Friese MA, Jones EY, Fugger L. MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol 2005; 26: 559-561.
27. Sundqvist E, Sundstrom P, Linden M, Hedstrom AK, Aloisi F, Hillert J et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 2012; 13: 14-20.
28. Sundstrom P, Nystrom M, Ruuth K, Lundgren E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J Neuroimmunol 2009; 215: 102-107.
29. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 2011; 76: 1989-1995.
30. Sundqvist E, Bergstrom T, Daialhosein H, Nystrom M, Sundstrom P, Hillert J et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler (e-pub ahead of print 2 September 2013; doi: 10.1177/1352458513494489).
31. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
32. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
33. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73: 696-701.
34. Piehl F, Holmen C, Hillert J, Olsson T. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 2011; 31(Suppl 3): 289-293.
35. Roos IM, Kockum I, Hillert J. The interleukin 23 receptor gene in multiple sclerosis: a case-control study. J Neuroimmunol 2008; 194: 173-180.
36. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62: 835-841.
37. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007; 357: 1199-1209.
38. Landin-Olsson M, Karlsson FA, Lernmark A, Sundkvist G. the Diabetes Incidence Study in Sweden group.. Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the Diabetes Incidence Study in Sweden. Diabetes 1992; 41: 1022-1027.
39. Jensen RA, Gilliam LK, Torn C, Landin-Olsson M, Karlsson FA, Palmer JP et al. Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects. J Diabetes Complications 2007; 21: 205-213.
40. Dahlquist G, Blom L, Tuvemo T, Nystrom L, Sandstrom A, Wall S. The Swedish childhood diabetes study-results from a nine year case register and a one year case-referent study indicating that type 1 (insulin-dependent) diabetes mellitus is associated with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders. Diabetologia 1989; 32: 2-6.
41. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 2001; 17: 983-989.
42. Eriksson P, Deguchi H, Samnegard A, Lundman P, Boquist S, Tornvall P et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 2004; 24: 551-557.
43. Ekelund E, Saaf A, Tengvall-Linder M, Melen E, Link J, Barker J et al. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. Am J Hum Genet 2006; 78: 1060-1065.
44. Prince JA, Feuk L, Howell WM, Jobs M, Emahazion T, Blennow K et al. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res 2001; 11: 152-162.
45. Roach JC, Deutsch K, Li S, Siegel AF, Bekris LM, Einhaus DC et al. Genetic mapping at 3-kilobase resolution reveals inositol 1,4,5-triphosphate receptor 3 as a risk factor for type 1 diabetes in sweden. Am J Hum Genet 2006; 79: 614-627.
46. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequencespecific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
47. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002; 51: 1346-1355.
48. Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, Nelson MR et al. Multi-population classical HLA type imputation. PLoS Comput Biol 2013; 9: e1002877.
49. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011; 13: 101.
50. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005; 20: 575-579.
51. R Development Core Team, 2011. R: A Language and Environment for Statistical Computing. In R Foundation for Statistical Computing: Vienna, Austria.
52. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.